<?xml version='1.0' encoding='utf-8'?>
<document id="24627219"><sentence text="A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer."><entity charOffset="56-66" id="DDI-PubMed.24627219.s1.e0" text="vinflunine" /><entity charOffset="87-97" id="DDI-PubMed.24627219.s1.e1" text="epirubicin" /><pair ddi="false" e1="DDI-PubMed.24627219.s1.e0" e2="DDI-PubMed.24627219.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24627219.s1.e0" e2="DDI-PubMed.24627219.s1.e1" /></sentence><sentence text="Vinflunine (VFL) is a bifluorinated tubulin-targeted agent of the vinca alkaloids class active in advanced stage breast cancer"><entity charOffset="0-10" id="DDI-PubMed.24627219.s2.e0" text="Vinflunine" /><entity charOffset="12-15" id="DDI-PubMed.24627219.s2.e1" text="VFL" /><entity charOffset="72-81" id="DDI-PubMed.24627219.s2.e2" text="alkaloids" /><pair ddi="false" e1="DDI-PubMed.24627219.s2.e0" e2="DDI-PubMed.24627219.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24627219.s2.e0" e2="DDI-PubMed.24627219.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24627219.s2.e0" e2="DDI-PubMed.24627219.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24627219.s2.e1" e2="DDI-PubMed.24627219.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24627219.s2.e1" e2="DDI-PubMed.24627219.s2.e2" /></sentence><sentence text=" We conducted a phase I study combining VFL with epirubicin (EPR) to establish the recommended dose (RD), to evaluate the safety and efficacy profiles and to investigate potential pharmacokinetic (PK) drug-drug interaction (DDI)"><entity charOffset="49-59" id="DDI-PubMed.24627219.s3.e0" text="epirubicin" /><entity charOffset="40-49" id="DDI-PubMed.24627219.s3.e1" text="VFL" /><pair ddi="false" e1="DDI-PubMed.24627219.s3.e1" e2="DDI-PubMed.24627219.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24627219.s3.e1" e2="DDI-PubMed.24627219.s3.e0" /></sentence><sentence text="" /><sentence text="Two schedules (day 1 every 3 weeks; days 1 and 8 every 3 weeks) were investigated as first-line chemotherapy of metastatic breast cancer patient" /><sentence text=" PK DDI was evaluated through population PK approaches" /><sentence text="" /><sentence text="Thirty-nine patients received a total of 197 cycles of the VFL-EPR combination (median 6)"><entity charOffset="59-61" id="DDI-PubMed.24627219.s8.e0" text="VFL" /></sentence><sentence text=" The RDs were VFL 250 mg/m(2) + EPR 75 mg/m(2) every 3 weeks for schedule 1 and VFL 170 mg/m(2) + EPR 35 mg/m(2) every 3 weeks for schedule 2"><entity charOffset="14-16" id="DDI-PubMed.24627219.s9.e0" text="VFL" /><entity charOffset="80-82" id="DDI-PubMed.24627219.s9.e1" text="VFL" /><pair ddi="false" e1="DDI-PubMed.24627219.s9.e0" e2="DDI-PubMed.24627219.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24627219.s9.e0" e2="DDI-PubMed.24627219.s9.e1" /></sentence><sentence text=" The PK analysis demonstrated no clinically relevant mutual DDI between VFL and EPR"><entity charOffset="72-74" id="DDI-PubMed.24627219.s10.e0" text="VFL" /></sentence><sentence text=" The main dose-limiting toxicity was neutropenia" /><sentence text=" The most frequent non-haematological adverse events were nausea, fatigue, constipation, vomiting, anorexia and stomatitis" /><sentence text=" Objective response rate was achieved in 45" /><sentence text="9 % of the patients" /><sentence text="" /><sentence text="VFL-EPR combination is feasible with manageable toxicity"><entity charOffset="0-2" id="DDI-PubMed.24627219.s16.e0" text="VFL" /></sentence><sentence text=" The antitumour activity was promising and supports further evaluation" /><sentence text="" /></document>